Early data hint at sub-blockbuster add-on for Alexion's billion dollar antibody
This article was originally published in Scrip
Alexion Pharmaceuticals has presented positive data from a Phase II single-arm study of its blockbuster Soliris (eculizumab) in a new potential indication, the prevention of antibody-mediated rejection (AMR), a severe and life-threatening complication in certain patients undergoing kidney transplantation. If the preliminary study findings are confirmed – they indicate that around 20% of kidney used in transplants might not be wasted through organ rejection - Alexion’s antibody could take a reasonable share in a $1.4bn market for kidney sparing in transplantation.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.